PE-backed Nexelis to buy ImmunXperts
Nexelis, a portfolio company of Ampersand Capital Partners, has agreed to acquire ImmunXperts, a Belgian provider of in-vitro immunology services.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
